Preliminary efficacy of fluticasone delivered by a novel device in recalcitrant chronic rhinosinusitis

Abstract

The OptiNose breath-actuated bi-directional delivery device administering fluticasone propionate (400 µg b.i.d.) is an effective and well tolerated treatment for recalcitrant CRS.